Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

Latest from Vanderbilt-Ingram Cancer Center


Mayer on the Optimization of SERDs in ER+ Breast Cancer

July 15, 2021

Dr. Mayer discusses the mechanism of action of SERDs in ER-positive breast cancer, highlighted data from the AMEERA-1 trial with amcenestrant and palbociclib, and details future research efforts with SERDs.

Lurbinectedin Makes a Splash in Second-Line SCLC

April 05, 2021

Wade T. Iams, MD, discusses the efficacy and safety of lurbinectedin in patients with small cell lung cancer, the impact of its approval on the paradigm, and remaining questions regarding its use.

Gastrointestinal Malignancies: Co-Chaired by Cathy Eng, MD, FACP, FASCO and Jordan D. Berlin, MD

January 27, 2021

Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of gastrointestinal malignancies.